Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET: Tirofiban with Alteplase in Acute Ischemic Stroke
NCT05188417Phase 2Unknown
- Sponsor
- Grand Pharmaceutical Group
- Start
- Dec 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tirofiban in acute ischemic stroke (AIS) (3 arms), sponsored by Grand Pharmaceutical Group. Primary endpoints: Symptomatic Intracranial Hemorrhage at 48 hours and Modified Rankin Scale Score 0-1 at 90 days. Status: unknown.
02
Drugs
tirofiban
03
Conditions
acute ischemic stroke (AIS)
Beyond the preview
Go deeper on NCT05188417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05188417.